Cargando…

Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis

BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao, Liu, Tao, Yin, Libin, Zuo, Didi, Lin, Yuyang, Wang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831235/
https://www.ncbi.nlm.nih.gov/pubmed/30817589
http://dx.doi.org/10.1097/MD.0000000000014659
_version_ 1783465922021818368
author Li, Chao
Liu, Tao
Yin, Libin
Zuo, Didi
Lin, Yuyang
Wang, Lei
author_facet Li, Chao
Liu, Tao
Yin, Libin
Zuo, Didi
Lin, Yuyang
Wang, Lei
author_sort Li, Chao
collection PubMed
description BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Science, PubMed, Embase, Cochrane Library, and Wanfang databases, as well as the China Biology Medicine disc (CBMdisc) and China National Knowledge Infrastructure (CNKI) were searched for studies on MUC1 expression and prognosis of CRC through July 20, 2018. The pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the prognostic and clinicopathological value of MUC1 expression in CRC. The Revman version 5.3 package and STATA, version 12 were employed for pooled analysis and analysis of publication bias. RESULTS: This meta-analysis included 16 published studies. The combined analysis showed that CRC patients with high MUC1 expression had a worse clinical outcome in overall survival (OS) (HR = 1.51, 95% CI = 1.30–1.75, P <.00001). In addition, high MUC1 expression was associated with higher TNM stage (RR = 1.44, 95% CI = 1.17–1.77, P = .0007), greater depth of invasion (RR = 1.30, 95% CI = 1.10–1.53, P = .002), and lymph node metastasis (RR = 1.47, 95% CI = 1.20–1.80, P = .0002) of CRC. However, the elevated MUC1 expression was not related to disease-free survival/recurrence-free survival (DFS/RFS) (HR = 1.51, 95% CI = 0.78–2.89, P = .22), histological grade (RR = 1.15, 95% CI = 0.96–1.38, P = .12), gender (RR = 0.95; 95% CI = 0.83–1.08, P = .44), tumor size (RR = 1.11, 95% CI = 0.85–1.44, P = .44), tumor site (RR = 1.01, 95% CI = 0.88–1.16, P = .84), or mucinous component (RR = 0.83, 95% CI = 0.60–1.14, P = .24) in CRC. CONCLUSION: Our findings indicated that high MUC1 expression represents a marker of poor prognosis in CRC. Meanwhile, elevated MUC1 expression was associated with advanced TNM stage, greater depth of invasion, and lymph node metastasis.
format Online
Article
Text
id pubmed-6831235
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-68312352019-11-19 Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis Li, Chao Liu, Tao Yin, Libin Zuo, Didi Lin, Yuyang Wang, Lei Medicine (Baltimore) 4500 BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Science, PubMed, Embase, Cochrane Library, and Wanfang databases, as well as the China Biology Medicine disc (CBMdisc) and China National Knowledge Infrastructure (CNKI) were searched for studies on MUC1 expression and prognosis of CRC through July 20, 2018. The pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the prognostic and clinicopathological value of MUC1 expression in CRC. The Revman version 5.3 package and STATA, version 12 were employed for pooled analysis and analysis of publication bias. RESULTS: This meta-analysis included 16 published studies. The combined analysis showed that CRC patients with high MUC1 expression had a worse clinical outcome in overall survival (OS) (HR = 1.51, 95% CI = 1.30–1.75, P <.00001). In addition, high MUC1 expression was associated with higher TNM stage (RR = 1.44, 95% CI = 1.17–1.77, P = .0007), greater depth of invasion (RR = 1.30, 95% CI = 1.10–1.53, P = .002), and lymph node metastasis (RR = 1.47, 95% CI = 1.20–1.80, P = .0002) of CRC. However, the elevated MUC1 expression was not related to disease-free survival/recurrence-free survival (DFS/RFS) (HR = 1.51, 95% CI = 0.78–2.89, P = .22), histological grade (RR = 1.15, 95% CI = 0.96–1.38, P = .12), gender (RR = 0.95; 95% CI = 0.83–1.08, P = .44), tumor size (RR = 1.11, 95% CI = 0.85–1.44, P = .44), tumor site (RR = 1.01, 95% CI = 0.88–1.16, P = .84), or mucinous component (RR = 0.83, 95% CI = 0.60–1.14, P = .24) in CRC. CONCLUSION: Our findings indicated that high MUC1 expression represents a marker of poor prognosis in CRC. Meanwhile, elevated MUC1 expression was associated with advanced TNM stage, greater depth of invasion, and lymph node metastasis. Wolters Kluwer Health 2019-03-01 /pmc/articles/PMC6831235/ /pubmed/30817589 http://dx.doi.org/10.1097/MD.0000000000014659 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle 4500
Li, Chao
Liu, Tao
Yin, Libin
Zuo, Didi
Lin, Yuyang
Wang, Lei
Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title_full Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title_fullStr Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title_full_unstemmed Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title_short Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
title_sort prognostic and clinicopathological value of muc1 expression in colorectal cancer: a meta-analysis
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831235/
https://www.ncbi.nlm.nih.gov/pubmed/30817589
http://dx.doi.org/10.1097/MD.0000000000014659
work_keys_str_mv AT lichao prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis
AT liutao prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis
AT yinlibin prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis
AT zuodidi prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis
AT linyuyang prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis
AT wanglei prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis